HC Wainwright set a $21.00 price target on Forty Seven (NASDAQ:FTSV) in a research note released on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also recently issued reports on the stock. FIG Partners started coverage on shares of Forty Seven in a report on Friday, February 1st. They set a buy rating and a $30.00 price objective for the company. Oppenheimer restated a buy rating on shares of Forty Seven in a report on Tuesday, March 19th. Guggenheim started coverage on shares of Forty Seven in a report on Friday, April 12th. They set a buy rating for the company. Finally, Zacks Investment Research cut shares of Forty Seven from a hold rating to a sell rating in a report on Wednesday, February 6th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $26.75.

Shares of NASDAQ:FTSV opened at $16.04 on Tuesday. Forty Seven has a one year low of $12.02 and a one year high of $23.83. The company has a market cap of $557.56 million and a PE ratio of -4.28.

Forty Seven (NASDAQ:FTSV) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Research analysts expect that Forty Seven will post -2.61 earnings per share for the current year.

In other Forty Seven news, insider Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $14.99, for a total value of $247,335.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Chris H. Takimoto sold 8,000 shares of Forty Seven stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $16.39, for a total transaction of $131,120.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 191,884 shares of company stock worth $3,348,369. Insiders own 37.40% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in FTSV. Bank of New York Mellon Corp bought a new position in Forty Seven in the third quarter valued at approximately $196,000. BlackRock Inc. lifted its stake in Forty Seven by 1,203.9% in the third quarter. BlackRock Inc. now owns 446,363 shares of the company’s stock valued at $6,659,000 after buying an additional 412,129 shares in the last quarter. Credit Suisse AG bought a new position in Forty Seven in the third quarter valued at approximately $209,000. JPMorgan Chase & Co. lifted its stake in Forty Seven by 51.2% in the third quarter. JPMorgan Chase & Co. now owns 346,066 shares of the company’s stock valued at $5,164,000 after buying an additional 117,142 shares in the last quarter. Finally, Teachers Advisors LLC bought a new stake in shares of Forty Seven in the third quarter worth $157,000. 43.70% of the stock is currently owned by hedge funds and other institutional investors.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Featured Article: What is a Call Option?

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.